Cytokinetics, Incorporated (NASDAQ:CYTK) Stock Quotes and News

Cytokinetics, Incorporated (CYTK) 1.19 0.05

Price Open:	1.14	Day's Range:	0.00000 - 1.45000
Price Close:	1.13	52wk Range:	0.00000 - 1.45000
Price Day Change:	0.05	Volume:	830,074
Price % Change:	4.42	Market Cap:	175.4M
Bid:	1.10000	PE Ratio:	0
Ask:	1.19000	EPS Diluted:	-0.353

Trade CYTK NOW!

The Latest On CYTK

UPDATE: Piper Jaffray Initiates Coverage on Cytokinetics with Overweight Rating, $4 PT 1/4/13 11:15am

Cytokinetics to Transfer Listing from NASDAQ Global Market to NASDAQ Capital Market 12/18/12 5:04pm

UPDATE: Dawson James Initiates Cytokinetics at Market Outperform on Competitive Positioning 11/27/12 1:02pm

Cytokinetics Offers Results from Phase IIA Trial of Tirasemtiv for Myasthenia Gravis 11/26/12 8:45am

Benzinga's Top Initiations 8/1/12 10:40am

UPDATE: Rodman & Renshaw Maintains Outperform on Cytokinetics; $2 PT 7/31/12 9:30am

Cytokinetics Announces Heart Failure Program Update 7/26/12 7:30am

Benzinga's Top Initiations 7/2/12 7:35am

Cytokinetics, Incorporated Announces $60 Million Financing 6/20/12 9:29am

Cytokinetics Announces Proposed Public Offerings of Common Stock and Warrants and Series B Convertible Preferred Stock and Warrants 6/19/12 4:23pm

Cytokinetics Receives NASDAQ Notice of Minimum Bid Price Non-Compliance 6/19/12 4:01pm

Cytokinetics Announces Opening of Second Cohort in Phase IIb Clinical Trial of Intravenous Omecamtiv Mecarbil in Patients With Acute Heart Failure 5/24/12 7:30am

Press Releases

Cytokinetics, Incorporated Reports First Quarter 2013 Financial Results 4/30/13 PR Thomson Reuters

Cytokinetics to Announce First Quarter Results on April 30, 2013 4/16/13 PR Thomson Reuters

Cytokinetics Announces Grant From Families with Spinal Muscular Atrophy for Preclinical Development of Tirasemtiv 4/4/13 PR Thomson Reuters

Cytokinetics Announces Initiation of First-Time-in-Humans, Phase I Clinical Trial of CK-2127107 4/1/13 PR Thomson Reuters

Cytokinetics Announces Presentation of Phase IIA Clinical Trial Data of Tirasemtiv in Patients with Myasthenia Gravis 3/21/13 PR Thomson Reuters

Cytokinetics Announces Update to Heart Failure Program 3/18/13 PR Thomson Reuters

Cytokinetics to Present Clinical Trial Data Relating to Tirasemtiv in Patients with Myasthenia Gravis 3/13/13 PR Thomson Reuters

Cytokinetics Announces Opening of COSMIC-HF, a Phase II Clinical Trial of Oral Formulations of Omecamtiv Mecarbil in Patients with Heart Failure 2/12/13 PR Thomson Reuters

Cytokinetics Announces Changes to Its Board of Directors 2/8/13 PR Thomson Reuters

Cytokinetics, Incorporated Reports Fourth Quarter 2012 Financial Results 2/5/13 PR Thomson Reuters

Cytokinetics to Announce Fourth Quarter Results on February 5, 2013 1/29/13 PR Thomson Reuters

Cytokinetics, Incorporated Receives NASDAQ Notice of Minimum Bid Price Compliance 1/25/13 PR Thomson Reuters

Get the latest CYTK stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Cytokinetics, Incorporated stock price.

Partner Headlines

Patients Dosed in Arena Study - Analyst Blog 4/9/13

AZN Reports Data on Fostamatinib - Analyst Blog 4/8/13

Data Presented on Bayer's ATX-101 - Analyst Blog 4/8/13

Cytokinetics Begins CK-2127107 Study - Analyst Blog 4/5/13

GHDX to Show Prostate Test Result - Analyst Blog 4/5/13

QLT Sells PPDS Technology - Analyst Blog 4/5/13

Glaxo Eyes Benlysta Label Expansion - Analyst Blog 4/5/13

Elan Gets Takeover Clarity - Analyst Blog 4/4/13

AstraZeneca Takes Over AlphaCore - Analyst Blog 4/4/13

Update on Protalix Gaucher Study - Analyst Blog 4/4/13

Orphan Status for Insmed's Arikace - Analyst Blog 4/4/13